Study shows improved survival in aggressive acute myeloid leukemia

Patients who relapse in their battle with acute myeloid leukemia may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *